Citation Impact
Citing Papers
Lysine Acetylation Targets Protein Complexes and Co-Regulates Major Cellular Functions
2009 StandoutScience
Factors Associated With Severe Late Toxicity After Concurrent Chemoradiation for Locally Advanced Head and Neck Cancer: An RTOG Analysis
2008 Standout
PD-1 expression by tumour-associated macrophages inhibits phagocytosis and tumour immunity
2017 StandoutNature
A meta-analysis of hyperfractionated and accelerated radiotherapy and combined chemotherapy and radiotherapy regimens in unresected locally advanced squamous cell carcinoma of the head and neck
2006
Epothilones – A fascinating family of microtubule stabilizing antitumor agents
2008
Survival Effect of Maximal Cytoreductive Surgery for Advanced Ovarian Carcinoma During the Platinum Era: A Meta-Analysis
2002 Standout
Randomised trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer
1998
Efficacy of epidermal growth factor receptor inhibitors versus chemotherapy as second-line treatment in advanced non-small-cell lung cancer with wild-type EGFR: A meta-analysis of randomized controlled clinical trials
2014
Physicians' view of practice guidelines. A survey of Italian physicians
1996
Docetaxel plus nintedanib versus docetaxel plus placebo in patients with previously treated non-small-cell lung cancer (LUME-Lung 1): a phase 3, double-blind, randomised controlled trial
2014
Why Don't Physicians Follow Clinical Practice Guidelines?
1999 Standout
Randomized Study Comparing Carboplatin/Cyclophosphamide and Cisplatin/Cyclophosphamide as First-Line Treatment in Patients with Stage III/IV Epithelial Ovarian Cancer and Small Volume Disease
1997
Second-line platinum therapy in patients with ovarian cancer previously treated with cisplatin.
1991 Standout
A view on drug resistance in cancer
2019 StandoutNature
Stem cells, cancer, and cancer stem cells
2001 StandoutNature
Cleavage of BID by Caspase 8 Mediates the Mitochondrial Damage in the Fas Pathway of Apoptosis
1998 Standout
Perspectives on cancer therapy-induced mucosal injury
2004 Standout
Tumour-associated macrophages are a distinct M2 polarised population promoting tumour progression: Potential targets of anti-cancer therapy
2006
Carboplatin with cyclophosphamide in patients with advanced ovarian cancer: an efficacy and quality-adjusted survival analysis
1992
The biology and management of non-small cell lung cancer
2018 StandoutNature
Hyperfractionated or accelerated radiotherapy in head and neck cancer: a meta-analysis
2006 Standout
Phase II study of BBR 3464 as treatment in patients with sensitive or refractory small cell lung cancer
2006
Dose calculation of anticancer drugs: a review of the current practice and introduction of an alternative.
1996 Standout
Metastatic non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
2016 Standout
New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
2008 Standout
Head and neck cancer
2008 Standout
Drug development from marine natural products
2008 Standout
Radiotherapy plus Cetuximab for Squamous-Cell Carcinoma of the Head and Neck
2006 Standout
Phase II studies of BBR3464, a novel tri-nuclear platinum complex, in patients with gastric or gastro-oesophageal adenocarcinoma
2004
Anthracyclines: Molecular Advances and Pharmacologic Developments in Antitumor Activity and Cardiotoxicity
2004 Standout
Swallowing dysfunction—preventative and rehabilitation strategies in patients with head-and-neck cancers treated with surgery, radiotherapy, and chemotherapy: A critical review
2003
Effect of body weight on the pharmacokinetics of cyclophosphamide in breast cancer patients
1987
Cetuximab Monotherapy and Cetuximab plus Irinotecan in Irinotecan-Refractory Metastatic Colorectal Cancer
2004 Standout
Afatinib versus erlotinib as second-line treatment of patients with advanced squamous cell carcinoma of the lung (LUX-Lung 8): an open-label randomised controlled phase 3 trial
2015
Cetuximab and Chemotherapy as Initial Treatment for Metastatic Colorectal Cancer
2009 Standout
Phase II Study of Trabectedin in Pretreated Patients with Advanced Colorectal Cancer
2007
A randomised study of carboplatin vs sequential ifosfamide/carboplatin for patients with FIGO stage III epithelial ovarian carcinoma
1993
Primary Surgery in Ovarian Cancer: Current Opinions
1995
Current and future perspectives of liquid biopsies in genomics-driven oncology
2018 Standout
Cisplatin-cyclophosphamide versus carboplatin-cyclophosphamide in advanced ovarian cancer: a randomized phase III study of the National Cancer Institute of Canada Clinical Trials Group.
1992
Meta-analysis of the literature or of individual patient data: is there a difference?
1993
Colorectal cancer
2019 Standout
Prospective Randomized Trials on Cytoreduction in Ovarian Cancer
1995
Surrogate endpoints for overall survival in locally advanced head and neck cancer: meta-analyses of individual patient data
2009
Saturable pharmacokinetics and paclitaxel pharmacodynamics in children with solid tumors.
1994
Thermodynamics of the interactions ofm-AMSA ando-AMSA with nucleic acids: influence of ionic strength and DNA base composition
1989
Immunity, Inflammation, and Cancer
2010 Standout
Chemotherapy with high dose ifosfamide/mesna plus cisplatin for the treatment of ovarian cancer: A study of the Grupo de Estudio y Tratamiento Latino‐Americano del cancer
1991
Carboplatin, doxorubicin, and cyclophosphamide versus cisplatin, doxorubicin, and cyclophosphamide: a randomized trial in stage III-IV epithelial ovarian carcinoma.
1991
Advanced epithelial ovarian carcinoma: Long-term survival experience at the community hospital
1992
Human Papillomavirus and Survival of Patients with Oropharyngeal Cancer
2010 Standout
Cytochrome c and dATP-Dependent Formation of Apaf-1/Caspase-9 Complex Initiates an Apoptotic Protease Cascade
1997 Standout
Therapeutic application of histone deacetylase inhibitors for central nervous system disorders
2008
Bid, a Bcl2 Interacting Protein, Mediates Cytochrome c Release from Mitochondria in Response to Activation of Cell Surface Death Receptors
1998 Standout
A model for p53-induced apoptosis
1997 StandoutNature
Leukocytes as a reservoir of circulating oncogenic DNA and regulatory targets of tumor‐derived extracellular vesicles
2018
Concomitant radiochemotherapy or accelerated radiotherapy: Analysis of two randomized trials of the French Head and Neck Cancer Group (GORTEC)
2004
Polynuclear platinum anticancer drugs are more potent than cisplatin and induce cell cycle arrest in glioma1
2006
Effects of Prolongation of Overall Treatment Time Due To Unplanned Interruptions During Radiotherapy of Different Tumor Sites and Practical Methods for Compensation
2007
Combined Carboplatin plus Ifosfamide and Cisplatin in Patients with Advanced Ovarian Carcinoma. A Phase I–II Study
1998
New Radiation Therapy Techniques for the Treatment of Head and Neck Cancer
2005
Long-term follow-up of the first randomized study of cisplatin versus carboplatin for advanced epithelial ovarian cancer.
1994
The Awareness-to-Adherence Model of the Steps to Clinical Guideline Compliance
1996
Adjuvant Chemotherapy for Stage II and III Colon Cancer Following Complete Resection: A Cancer Care Ontario Systematic Review
2017
Early colon cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
2013
Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial
2000 Standout
Anticancer drug design based on plant-derived natural products
1999
Molecular therapies and precision medicine for hepatocellular carcinoma
2018
The adoption of preventive care practice guidelines by primary care physicians
1995
Improved prognosis of ovarian cancer in The Netherlands during the period 1975–1985: A registry-based study
1991
The status of platinum anticancer drugs in the clinic and in clinical trials
2010 Standout
Practical methods for incorporating summary time-to-event data into meta-analysis
2007 Standout
Up-regulation of Apoptosis Inhibitory Protein IAP-2 by Hypoxia
2001 StandoutNobel
Cancer related inflammation: The macrophage connection
2008
Feedback and redundancy in receptor tyrosine kinase signaling: relevance to cancer therapies
2014
The PRISMA Statement for Reporting Systematic Reviews and Meta-Analyses of Studies That Evaluate Health Care Interventions: Explanation and Elaboration
2009 Standout
High-Dose Platinum versus Standard Dose in Advanced Ovarian Carcinoma: A Randomized Trial from the Gynecologic Cooperative Group of the French Comprehensive Cancer Centers (FNCLCC)
2000
Biomarker-driven and molecular targeted therapies for colorectal cancers
2017
Defects in the Ubiquitin Pathway Induce Caspase-independent Apoptosis Blocked by Bcl-2
1998 StandoutNobel
The Next Generation of Platinum Drugs: Targeted Pt(II) Agents, Nanoparticle Delivery, and Pt(IV) Prodrugs
2016 Standout
Hepatocellular Carcinoma
2019 Standout
Randomized trial of initial therapy with melphalan versus cisplatin-based combination chemotherapy in patients with advanced ovarian carcinoma: Initial and long term results—Eastern Cooperative Oncology Group study E2878
1996
Drug Discovery and Natural Products: End of an Era or an Endless Frontier?
2009 StandoutScience
G2 delay induced by nitrogen mustard in human cells affects cyclin A/cdk2 and cyclin B1/cdc2-kinase complexes differently.
1993 StandoutNobel
Prevention of Apoptosis by Bcl-2: Release of Cytochrome c from Mitochondria Blocked
1997 StandoutScience
Randomized Phase III Trial of Erlotinib Versus Docetaxel As Second- or Third-Line Therapy in Patients With Advanced Non–Small-Cell Lung Cancer: Docetaxel and Erlotinib Lung Cancer Trial (DELTA)
2014
Etoposide pharmacokinetics in patients with normal and abnormal organ function.
1986
Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors vs Conventional Chemotherapy in Non–Small Cell Lung Cancer Harboring Wild-Type Epidermal Growth Factor Receptor
2014
Phase I trial of escalating pentoxifylline dose with constant dose thiotepa.
1990
NF-κB Antiapoptosis: Induction of TRAF1 and TRAF2 and c-IAP1 and c-IAP2 to Suppress Caspase-8 Activation
1998 StandoutScience
Pemetrexed versus erlotinib in pretreated patients with advanced non–small cell lung cancer: A Hellenic Oncology Research Group (HORG) randomized phase 3 study
2013
Cell and Environment Interactions in Tumor Microregions: The Multicell Spheroid Model
1988 StandoutScience
Treatment of Disseminated Germ-Cell Tumors with Cisplatin, Bleomycin, and either Vinblastine or Etoposide
1987 Standout
CRISPR-enhanced engineering of therapy-sensitive cancer cells for self-targeting of primary and metastatic tumors
2018
Original article: Five year follow-up and dose delivery analysis of cisplatin, iproplatin or carboplatin in combination with cyclophosphamide in advanced ovarian carcinoma
1990
The biology , function , and biomedical applications of exosomes
2020 StandoutScience
Integrating Systemic Therapies into the Multimodality Treatment of Resectable Colorectal Liver Metastases
2018
Chemotherapy Options for Patients With Metastatic or Recurrent Squamous Cell Carcinoma of the Head and Neck
2006
A structural basis for a phosphoramide mustard-induced DNA interstrand cross-link at 5'-d(GAC).
1995 StandoutNobel
Mitochondria and Apoptosis
1998 StandoutScience
Objective Responses in Patients with Malignant Melanoma or Renal Cell Cancer in Early Clinical Studies Do Not Predict Regulatory Approval
2005
New Perspectives on an Old Friend: Optimizing Carboplatin for the Treatment of Solid Tumors
1998
Considerations in the Design of Possible Cell Cycle Effective Drugs
1986
Inhibitors of human immunodeficiency virus integrase.
1993 StandoutNobel
Metabolism of oxazaphosphorines
1988
Physicians’ Reactions to Change in Recommendations for Mammography Screening
1997
Systemic Therapy for Stage IV Non–Small-Cell Lung Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update
2015
Structural Basis of Type II Topoisomerase Inhibition by the Anticancer Drug Etoposide
2011 StandoutScience
Photopharmacology: Beyond Proof of Principle
2014 StandoutNobel
Five‐year survival for cisplatin‐based chemotherapy versus single‐agent melphalan in patients with advanced ovarian cancer and optimal debulking surgery
1991
Staging Procedures, Clinical Management, and Survival Outcome for Ovarian Carcinoma
1993
Regulation of Cell Death Protease Caspase-9 by Phosphorylation
1998 StandoutScience
Nontoxic nanopore electroporation for effective intracellular delivery of biological macromolecules
2019 StandoutNobel
Works of Silvia Marsoni being referenced
Defective Mismatch Repair As a Predictive Marker for Lack of Efficacy of Fluorouracil-Based Adjuvant Therapy in Colon Cancer
2010
Inhibition of MEK and PI3K/mTOR Suppresses Tumor Growth but Does Not Cause Tumor Regression in Patient-Derived Xenografts of RAS-Mutant Colorectal Carcinomas
2012
Clinical drug development: an analysis of phase II trials, 1970-1985.
1987
Process and outcome of care for patients with ovarian cancer.
1985
GIVIO-SITAC 01
1998
DNA Mismatch Repair Status and Colon Cancer Recurrence and Survival in Clinical Trials of 5-Fluorouracil-Based Adjuvant Therapy
2011
Clinical and pharmacological phase I study with accelerated titration design of a daily times five schedule of BBR3464, a novel cationic triplatinum complex
2000
Integrating liquid biopsies into the management of cancer
2017
Phase IB and pharmacological study of the novel taxane BMS-184476 in combination with doxorubicin
2004
Critical review of the quality and development of randomized clinical trials (RCTs) and their influence on the treatment of advanced epithelial ovarian cancer
1990
A work in progress: The clinical development of histone deacetylase inhibitor
2008
Phase I clinical study of the novel epothilone B analogue BMS-310705 given on a weekly schedule
2007
Erlotinib versus docetaxel as second-line treatment of patients with advanced non-small-cell lung cancer and wild-type EGFR tumours (TAILOR): a randomised controlled trial
2013
Randomized Trial in Advanced Ovarian Cancer Comparing Cisplatin and Carboplatin
1989
The Impact of Patient Management Guidelines on the Care of Breast, Colorectal, and Ovarian Cancer Patients in Italy
1991
Locoregionally advanced carcinoma of the oropharynx: conventional radiotherapy vs. accelerated hyperfractionated radiotherapy vs. concomitant radiotherapy and chemotherapy—a multicenter randomized trial
2002
Prognostic factors in advanced epithelial ovarian cancer
1990
Plasma levels of cyclophosphamide in patients under polychemotherapeutic regimens.
1980
Tolerance to antineoplastic agents in children and adults.
1985
Trabectedin for Women With Ovarian Carcinoma After Treatment With Platinum and Taxanes Fails
2005
Spiromustine: a new agent entering clinical trials
1983
Therapeutic response in phase I trials of antineoplastic agents.
1986
Clinical development of anticancer agents--a National Cancer Institute perspective.
1984
Etoposide (VP-16–213)
1985
Therapeutic dual inhibition of HER2 pathway for metastatic colorectal cancer (mCRC): The HERACLES trial.
2015
TAILOR: Phase III trial comparing erlotinib with docetaxel in the second-line treatment of NSCLC patients with wild-type (wt) EGFR.
2012
420 Conventional radiotherapy versus accelerated hyperfractionated radiotherapy versus conventional radiotherapy and concomitant chemotherapy in advanced oropharyngeal carcinoma: A randomized clinical trial
1995
Randomized comparison of hexamethylmelamine, adriamycin, cyclophosphamide (hac) vs. cisplatin, adriamycin, cyclophosphamide (pac) in advanced ovarian cancer: long-term results
1991
Teniposide: a review of 12 years of experience.
1984